# Single centre study comparing results of pathologic analysis of EUS-FNA with EUS-TCB in patients with enlarged mediastinal lymph nodes and evaluating mutation analysis on EUS-TCB in patients with NSCLC.

Published: 24-05-2011 Last updated: 29-04-2024

To compare the feasibility of mutation analysis in samples obtained with EUS-FNA and EUS-TCB in patients with mediastinal lymph node metastasis in NSCLC. To compare EUS-TCB with EUS-FNA in diagnosing benign and malignant mediastinal disease.

Ethical review	Not approved
Status	Will not start
Health condition type	Respiratory and mediastinal neoplasms malignant and unspecified
Study type	Observational invasive

# Summary

### ID

NL-OMON35924

**Source** ToetsingOnline

**Brief title** Assessment of EUS-FNA compared to EUS-FNA and EUS-TCB.

# Condition

• Respiratory and mediastinal neoplasms malignant and unspecified

#### Synonym

enlarged lymfnodes and malignancy

#### **Research involving**

1 - Single centre study comparing results of pathologic analysis of EUS-FNA with EUS  $\ldots$  6-05-2025

Human

# **Sponsors and support**

Primary sponsor: Isala Klinieken Source(s) of monetary or material Support: ziekenhuis

### Intervention

Keyword: diagnosis, EUS-FNA, EUS-TCB, mutation analysis

### **Outcome measures**

#### **Primary outcome**

Pathologic diagnosis; mutation analysis in NSCLC

#### Secondary outcome

Complications

# **Study description**

#### **Background summary**

Endoscopic ultrasound guided fine-needle aspiration is a widely used diagnostic tool in the analysis and staging of lung cancer and mediastinal lymphadenopathy in other diseases.

EUS-FNA has a sensitivity of 88-96% and a specificity of almost 100% and accuracy of  $95\%1,\,2$  .

In the gastroenterology trucut biopsy (EUS-TCB) is a proven diagnostic tool in the evaluation of benign and malignant disease, as well as in staging malignant tumours of the gastrointestinal tract 3.

In mediastinal lesions too EUS-TCB is an accurate method. There is a diagnostic accuracy of 98% in combination with EUS-FNA 4.

Molecular analysis for EGFR and KRAS mutations evolved to increasing relevance and is rapidly developing to standard practice in stage IV NSCLC5. Most mutation analysis has been done on histologic samples, however more and more studies report on molecular diagnostics on cytological material too (using High resolution melting6), it is not clear if this method has a better specificity and sensitivity than mutation analysis on histological material.

In this study the pathologic results of histologic and cytologic samples of

mediastinal lymph nodes obtained with EUS-TCB respectively EUS-FNA are compared in order to evaluate the added value of histology in the diagnosis of malignant and benign mediastinal disease.

Moreover the feasibility of molecular analysis in EUS-TCB and EUS-FNA derived samples is compared for patients with a diagnosis of NSCLC.

We also want to score the complication rate. In the gastroenterology a complication rate of 2% is described in EUS-FNA as in EUS-TCB (infection and bleeding)7.

#### **Study objective**

To compare the feasibility of mutation analysis in samples obtained with EUS-FNA and EUS-TCB in patients with mediastinal lymph node metastasis in NSCLC.

To compare EUS-TCB with EUS-FNA in diagnosing benign and malignant mediastinal disease.

#### Study design

Prospective, open, single-arm, single-centre trial

#### Study burden and risks

Little additional load (the test takes around 5minuten longer) plus additional punctures, which are generally not felt.

# Contacts

**Public** Isala Klinieken

Groot Wezenland 20 8000 GM Zwolle Nederland **Scientific** Isala Klinieken

Groot Wezenland 20 8000 GM Zwolle Nederland

# **Trial sites**

# **Listed location countries**

Netherlands

# **Eligibility criteria**

Age Adults (18-64 years) Elderly (65 years and older)

### **Inclusion criteria**

- 1. Patients with large mediastinal lymph nodes (>2cm) at location N7, N4L on CT or PET-CT.
- 2. Age of 18-85 years.
- 3. ASA classification 1 3

### **Exclusion criteria**

- 1. ASA classification > 3 (see appendix A)
- 2. Obstructing oral or laryngeal disease.
- 3. Severe maxillofacial deformity.

# Study design

### Design

Study type: Observational invasive		
Masking:	Open (masking not used)	
Control:	Uncontrolled	
Primary purpose:	Diagnostic	

### Recruitment

NL Recruitment status:

Will not start

4 - Single centre study comparing results of pathologic analysis of EUS-FNA with EUS ... 6-05-2025

Enrollment: Type: 102 Anticipated

# **Ethics review**

Not approvedDate:24-05-2011Application type:First submissionReview commission:METC Isala Klinieken (Zwolle)

# **Study registrations**

# Followed up by the following (possibly more current) registration

No registrations found.

# Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register CCMO ID NL36627.075.11